07:45 AM EDT, 06/13/2025 (MT Newswires) -- Beam Therapeutics ( BEAM ) said updated results from 17 patients in its phase 1/2 BEACON trial evaluating BEAM-101, a base-editing therapy for severe sickle cell disease, showed "robust and durable" increases in fetal hemoglobin, reduced sickle hemoglobin, and normalized hemolysis markers.

The company will present the new safety and efficacy data at the EHA2025 Congress in Milan on Friday.

No vaso-occlusive crises were reported after engraftment, the company said.

Beam said it has completed enrollment in both adult and adolescent cohorts, with 26 patients dosed as of Friday and 30 expected by mid-2025. The company will provide additional data by year-end.